Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less

Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals

Asahi Kasei opens new Bioprocess Technical Center in China

The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics

Asahi Kasei Pharma files application for approval to manufacture and sell Cresemba Capsule

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Asahi Kasei completes construction of microcrystalline cellulose plant

With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC

Asahi Kasei Medical to acquire US based CDMO Bionova Scientific

Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture

Asahi Kasei to build new production unit for membrane virus filters in Japan

The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market